-
公开(公告)号:US20180244746A1
公开(公告)日:2018-08-30
申请号:US15756091
申请日:2016-09-16
申请人: INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DESCARTES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
IPC分类号: C07K14/725 , C12Q1/6881 , C12N15/86 , G01N33/566
CPC分类号: C07K14/7051 , C07K2319/00 , C07K2319/33 , C12N15/86 , C12Q1/6881 , G01N33/566 , G01N2333/7051
摘要: The present invention relates to T-cell receptors (TCR) that recognize pancreatic betacell epitopes and uses thereof for the diagnosis and treatment of diabetes.
-
2.
公开(公告)号:US20180207250A1
公开(公告)日:2018-07-26
申请号:US15745273
申请日:2016-07-13
申请人: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE PARIS DESCARTES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) , UNIVERSITE PARIS DIDEROT - PARIS 7 , UNIVERSITÉ PARIS-SUD , SORBONNE UNIVERSITE
CPC分类号: A61K39/0008 , A61K2039/542 , A61K2039/577 , A61K2039/6056 , A61P37/06
摘要: The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety.
-
公开(公告)号:US20210023209A1
公开(公告)日:2021-01-28
申请号:US16981462
申请日:2019-03-15
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE PARIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
发明人: Roberto MALLONE , Yann VERDIER , Joëlle VINH , Marie-Eliane AZOURY , Sergio GONZALEZ-DUQUE , Georgia AFONSO
IPC分类号: A61K39/395 , C07K14/47 , C07K14/725 , C12N15/115 , C12N15/62
摘要: Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. PCSK2 was identified as a novel β-cell antigen, which was processed into HLA-A2-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from PCSK2 and uses thereof for the diagnosis and treatment of T1D.
-
公开(公告)号:US20210024603A1
公开(公告)日:2021-01-28
申请号:US16981474
申请日:2019-03-15
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE PARIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
发明人: Roberto MALLONE , Sergio GONZALEZ-DUQUE , Yann VERDIER , Marie-Eliane AZOURY , Georgia AFONSO , Joëlle VINH
IPC分类号: C07K14/575 , C12N15/115 , C07K16/26 , C07K14/74
摘要: Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.
-
公开(公告)号:US20210070819A1
公开(公告)日:2021-03-11
申请号:US16981352
申请日:2019-03-15
申请人: INSERM (Institut National de la Santé et de la Recherche Médicale) , Universite de Paris , Centre National de la Recherche Scientifique (CNRS) , Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris , Université Libre de Bruxelles
发明人: Roberto MALLONE , Joëlle VINH , Yann VERDIER , Decio LAKS EIZIRIK , Maikel Luis COLLI , Georgia AFONSO , Sergio GONZALEZ-DUQUE
摘要: Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (TID), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Secretogranin V (SCG5/7B2) was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. HLA-A2-bound neo-epitopes were also represented and originated from an alternative SCG5-009 mRNA splice isoform. Accordingly, the present invention relates to antigenic peptides derived from secretogranin V and uses thereof for the diagnosis and treatment of T1D.
-
-
-
-